Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
233400
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of the 7th Series of Stock Acquisition Rights (paid stock options)
Who receives how much
233,400 common shares (2,334 Stock Acquisition Rights, 100 shares per right)
3 directors of the Company233,400 shares (2,334 Stock Acquisition Rights)
The lower thin line represents the existing number of shares to which these shares will be added.
¥100 per Stock Acquisition Right
発行済株式総数
Approximately 5.5% (based on 4,244,277 issued shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Based on ¥508 per share. The exercise price is calculated as the closing price on 5 November 2026 multiplied by 105%, with adjustment provisions applying in the event of a stock split, consolidation or other such event.
Exercise period
From 27 November 2026 to 26 November 2036
Number of Stock Acquisition Rights
Total issued: 2,334. Number of outstanding unexercised rights: Not disclosed
Reason for acquisition without consideration
If approval or other authorisation is granted for a merger in which the Company is the disappearing company, a company split in which the Company is the splitting company, or a share exchange or share transfer in which the Company becomes a wholly owned subsidiary, the Company may acquire all of these Stock Acquisition Rights free of charge.
Categories and Number of Persons Covered
3 Company directors, 2,334 Stock Acquisition Rights (233,400 shares)
Payment date
27 November 2026
Basis for determining the amount to be paid
The exercise price is the closing price of the Company's common shares on the Tokyo Stock Exchange on 5 November 2026 multiplied by 105%. The issue price of the Stock Acquisition Rights is based on the fair value calculated by an independent valuation institution using a Monte Carlo simulation.
Procedures under the Corporate Code of Conduct
Because the rights are issued for consideration at fair value and the terms are not particularly favourable, the issuance was resolved by the Board of Directors without approval at a general meeting of shareholders. The directors to whom the rights are allotted did not participate in the individual deliberations or resolution as specially interested parties.
Most recent equity financing
Timing 6 November 2026 / Type Series 6 Stock Acquisition Rights (tax-qualified stock options) / Amount Stock Acquisition Rights for 84,800 underlying shares
Impact on Business Performance
The specific impact on performance at this time is Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of the 7th Series of Stock Acquisition Rights (paid stock options) |
| Number of shares to be issued or disposed of | 233,400 common shares (2,334 Stock Acquisition Rights, 100 shares per right) |
| Issue price and disposal price | ¥100 per Stock Acquisition Right |
| Payment date | 27 November 2026 |
| Intended allottee | Category 3 directors of the Company / Number of Shares 233,400 shares (2,334 Stock Acquisition Rights) |
| Dilution Rate | Approximately 5.5% (based on 4,244,277 issued shares) |
| Total number of issued shares | 4,244,277 shares (excluding treasury shares) → Not disclosed |
| Basis for determining the amount to be paid | The exercise price is the closing price of the Company's common shares on the Tokyo Stock Exchange on 5 November 2026 multiplied by 105%. The issue price of the Stock Acquisition Rights is based on the fair value calculated by an independent valuation institution using a Monte Carlo simulation. |
| Exercise price | Based on ¥508 per share. The exercise price is calculated as the closing price on 5 November 2026 multiplied by 105%, with adjustment provisions applying in the event of a stock split, consolidation or other such event. |
| Exercise period | From 27 November 2026 to 26 November 2036 |
| Number of Stock Acquisition Rights | Total issued: 2,334. Number of outstanding unexercised rights: Not disclosed |
| Reason for acquisition without consideration | If approval or other authorisation is granted for a merger in which the Company is the disappearing company, a company split in which the Company is the splitting company, or a share exchange or share transfer in which the Company becomes a wholly owned subsidiary, the Company may acquire all of these Stock Acquisition Rights free of charge. |
| Categories and Number of Persons Covered | 3 Company directors, 2,334 Stock Acquisition Rights (233,400 shares) |
| Procedures under the Corporate Code of Conduct | Because the rights are issued for consideration at fair value and the terms are not particularly favourable, the issuance was resolved by the Board of Directors without approval at a general meeting of shareholders. The directors to whom the rights are allotted did not participate in the individual deliberations or resolution as specially interested parties. |
| Most recent equity financing | Timing 6 November 2026 / Type Series 6 Stock Acquisition Rights (tax-qualified stock options) / Amount Stock Acquisition Rights for 84,800 underlying shares |
| Impact on Business Performance | The specific impact on performance at this time is Not disclosed |
Items this document does not state (12)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyTransfer restriction periodConditions for lifting transfer restrictionsTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To raise the directors' motivation and morale with the aim of expanding the Group's performance and increasing corporate value over the medium to long term, and to encourage them to share the risk of a decline in the share price with existing shareholders, thereby increasing their motivation to enhance corporate value.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.